MedTrace Logo

Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma

NCT00848640 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2010-05-26

No results posted yet for this study

Summary

The purpose study is to evaluate the efficacy and safety of Sorafenib as first line treatment for patients - unsuitable for another approved first line therapy - with advanced RCC in the Middle East Region.

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

DRUG

Sorafenib

400 mg twice daily

Sponsors & Collaborators

  • Egyptian Foundation For Cancer Research

    lead OTHER

Principal Investigators

  • Hussein M. Khaled, MD · Egyptian Foundation For Cancer Research

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2009-12-31
Completion
2010-03-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00848640 on ClinicalTrials.gov